Data presented at the American Academy of Dermatology's annual meeting – June 12-14

Company Product Description Indication Status
Concert Pharmaceuticals Inc., of Lexington, Mass. CTP‑543  Inhibitor of JAK1 and JAK2 Moderate to severe alopecia areata In the phase II study, 8 mg and 12 mg twice daily produced a Severity of Alopecia Tool (SALT) score of 20 or less in 26% and 42% of patients, respectively, at week 24 (p <0.05 vs. placebo); 36% of patient taking 12-mg dose achieved a SALT score of 10 or less; 61% and 75% of clinicians rated the response as much improved or very much improved at week 24 for the 8-mg and 12-mg doses, respectively
Brickell Biotech Inc., of Boulder, Colo., and Kaken Pharmaceutical Co. Ltd., of Tokyo Sofpironium bromide gel Blocks acetylcholine Primary axillary hyperhidrosis In the phase III study, 53.9% of patients taking the drug had a response, defined as a score of 1 or 2 on the Hyperhidrosis Disease Severity Scale and at least a 50% reduction in gravimetric sweat production, compared to 36.4% of patient treated with vehicle (p=0.003); drug changed HDSM-Ax score by -1.41 vs. -0.93 for vehicle (p=0.001)
Eli Lilly and Co., of Indianapolis Lebrikizumab  Monoclonal antibody targeting IL-13  Moderate to severe atopic dermatitis In the phase IIb study, drug improved itch by day 2 with further improvement to week 16, sleep by the first on-treatment assessment at week 1 with further improvement to week 16, Patient-Oriented Eczema Measure score by the first on-treatment assessment at week 16, dermatology health-related quality of life scores by the first on-treatment assessment at week 8 and patient global assessment of change at week 16
Janssen Pharmaceutical Co., part of New Brunswick, N.J.-based Johnson & Johnson Tremfya (guselkumab) Monoclonal antibody targeting the p19 subunit of interleukin-2 Moderate to severe plaque psoriasis In the open-label extension of the phase III Voyage 2 study, 80% of patients who were treated with Tremfya for 4 years achieved at least 90% improvement in the Psoriasis Area and Severity Index (PASI 90) score; 82% of patients achieved an Investigator’s Global Assessment score of clear or minimal disease; 51% achieved PASI 100; in the phase III Voyage 1 study, 42% of patients treated with Tremfya had a Psoriasis Symptoms and Signs Diary (PSSD) symptom score of 0, at week 48 compared to 23% of patients taking Humira (adalimumab) (p<0.001); 36% of patients had a PSSD sign score of 0 compared to 19% of patients taking Humira (p<0.001)
Leo Pharma A/S, of Ballerup, Denmark Tralokinumab  Monoclonal antibody targeting IL-13 Moderate to severe atopic dermatitis In the phase III Ecztra 1 and 2 studies, at week 16, 16% and 22%, respectively, of patients taking tralokinumab had an Investigator Global Assessment score of clear or almost clear skin (IGA 0/1) compared to 7% and 11%, respectively, of patients taking placebo (p=0.002 and p<0.001, respectively); 25% and 33%, respectively, of patients taking tralokinumab had at least a 75% improvement in Eczema Area and Severity Index (EASI-75) score compared to 13% and 11%, respectively of patients taking placebo (p<0.001 for both); in the phase III Ecztra 3 study, 39% of patients taking tralokinumab plus topical corticosteroid achieved IGA 0/1 and 56% achieved EASI-75 compared to 26% and 36%, respectively, of patients taking topical corticosteroid alone (p=0.015 and p<0.001, respectively)
Leo Pharma A/S, of Ballerup, Denmark Enstilar (calcipotriene and betamethasone dipropionate) Vitamin D analogue and a corticosteroid Plaque psoriasis In the phase III PSO-LONG trial, 80% of the 650 patients achieved treatment success, defined as Physician Global Assessment score of clear or almost clear with a minimum 2-grade improvement from baseline, after 4 weeks; those patients were randomized to drug or vehicle, and the median time to relapse was 56 days for drug vs. 30 days for vehicle; risk of relapse was 43% lower for drug compared to vehicle (p<0.001); rate of relapse over 1 year was 46% lower for drug vs. placebo (p<0.001)
Principia Biopharma Inc., of South San Francisco Rilzabrutinib  Bruton’s tyrosine kinase inhibitor Mild to severe pemphigus In the phase II study, treatment with rilzabrutinib reduced corticosteroid usage from 18 mg/day at baseline to 11 mg/day at 12 weeks and 6 mg/day at 24 weeks for the 14 patients who completed 24 weeks of treatment

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments